Apex Infusion Agrees to SkyKnight Capital Partnership

Apex Infusion has entered a definitive agreement to partner with SkyKnight Capital, adding a new private equity sponsor as the alternate-site infusion provider prepares for its next phase of expansion. Under the agreement announced on July 24, 2026, Apex's clinician-led management team will retain a significant ownership stake and continue leading the company, while FFL Partners will remain a minority investor.

The financial terms and ownership percentages were not disclosed, and the transaction remains subject to customary closing conditions and required regulatory approvals. What is public is the operating thesis: SkyKnight is expected to support expansion into new markets, partnerships with health systems and payors, and technology-enabled initiatives designed to improve patient access.

What Happened

Apex is not announcing a conventional venture financing with a clearly defined stage and headline valuation. Instead, the company has entered into a private equity partnership with SkyKnight Capital, a firm managing approximately $6.5B across healthcare, financial services, and tech-enabled services investments. SkyKnight Managing Director Don Wu said the firm plans to work alongside Apex's leadership and FFL Partners to build the company as a leading alternate-site infusion partner for patients, providers, and payors.

Continuity is built into the transaction. Moussie Haile, PharmD, will remain CEO and co-founder, while Rick Smith will continue as Executive Chairman and co-founder. Their continued leadership matters because Apex's business depends on more than capital and real estate. It relies on clinical operations, pharmacy coordination, nursing capacity, provider relationships, payor workflows, and a patient experience that can withstand expansion.

Why This Matters

Founded in 2006 and headquartered in Signal Hill, California, Apex delivers infusion therapy through in-home nurses and private ambulatory infusion suites. Its service model encompasses the work surrounding treatment itself, including provider referrals, insurance authorization, medication coordination, delivery, nurse administration, and ongoing patient support.

That operating chain explains why alternate-site infusion businesses are more difficult to scale than their facility count alone suggests. Opening another infusion suite creates capacity, but the company must still earn referrals, coordinate specialty medications, meet clinical standards, and deliver a consistent patient experience across locations. Capital is important, but the repeatable operating model is the real asset.

The clearest evidence of Apex's growth is physical expansion. When FFL Partners completed its investment in June 2024, Apex operated 11 locations across California. The July 2026 announcement describes approximately 40 ambulatory infusion suite locations supported by an extensive network of home-infusion nurses.

That comparison does not reveal revenue, patient volume, market share, or valuation, nor should it be treated as a substitute for those metrics. It does show that Apex significantly expanded its care-delivery footprint during FFL's ownership, giving SkyKnight more than a presentation deck to underwrite. The next phase will test whether that operating model can expand into additional markets while maintaining consistency.

The Investor Logic

SkyKnight's interest in Apex aligns with its focus on acyclical growth sectors and management-led businesses. Infusion care is clinically necessary, operationally complex, and built on relationships among patients, physicians, pharmacies, health systems, and insurers. A company capable of coordinating those stakeholders across home and ambulatory settings is building critical healthcare infrastructure, even if it looks very different from the software infrastructure that dominates technology headlines.

FFL Partners' decision to remain a minority investor adds another important signal. The existing sponsor is not exiting the investment, and Apex's management team is retaining meaningful ownership. That structure aligns three groups around the next stage of growth: the clinical operators who built the platform, an investor that has already watched the company scale, and a new sponsor bringing additional healthcare expertise and capital.

The announcement identifies three priorities. Apex plans to expand into new markets, pursue strategic relationships with health systems and payors, and develop technology-enabled initiatives that improve patient access. Those objectives define the work ahead, but execution will matter far more than the language announcing them.

Market expansion will require local clinical talent, referral relationships, pharmacy coordination, nursing capacity, and disciplined regulatory execution. Health-system and payor partnerships will require Apex to demonstrate that its model consistently delivers high-quality care in alternate settings. Technology can reduce administrative friction, but the company has not disclosed a proprietary platform, detailed product roadmap, or technology stack. The central story remains the operating system surrounding care rather than an assumed software platform.

The Bigger Industry Shift

Apex operates within a broader movement to deliver appropriate infusion care outside traditional hospital settings. The company gives patients the choice between in-home treatment and private ambulatory infusion suites, while the transaction announcement identifies patient access, clinical quality, and lower costs of care as core differentiators. That is fundamentally a healthcare-services strategy with technology supporting clinical workflows rather than replacing clinicians.

For operators and investors, the lesson is straightforward. Growth in healthcare is not driven solely by discovering new therapies. It also depends on building better ways for proven therapies to reach patients. Apex has turned that delivery pathway into a coordinated service, and SkyKnight is investing in the belief that the model can expand without sacrificing the clinical culture that made it successful.

The first milestone is closing the transaction. The agreement still must satisfy customary closing conditions and receive the required regulatory approvals, and no closing timeline has been announced. Until then, the partnership should be described as pending rather than completed.

After closing, the meaningful measures will be operational. Which markets does Apex enter? Which health-system and payor relationships does it establish? How does its infusion-suite network evolve? Which technology-enabled patient access initiatives become real? The transaction value may remain private, but execution will be visible through the company's footprint, partnerships, and ability to preserve consistent care as the platform grows.